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List of abbreviations ANOVA  analysis of variance: statistical tool, amongst other functions used for    phylogenetic interpretations of clade-specific properties ATP  adenosine triphosphate: coenzyme essential for intracellular energy transfer C.   abbreviation for the genus Candida CABI   Candida albicans bloodstream isolate CBP   clinical breakpoint: interpretation of the relevance of an antifungal MIC for   clinical therapy Cdr1, Cdr2  Candida drug resistance transporter: Multidrug transporter; transport    phospholipids in an in-to-out direction CFU   colony forming units (used to inoculate agar medium dishes) CLSI   Clinical and laboratory standard institute DST   diploid sequence type: defined by an MLST-profile of 7 gene fragments ECOFF/ECV  epidemiological cutoff value: splitting populations in wild-type and non-   wild-type due to their statistical MIC distribution Erg3p   C-5 sterol desaturase: catalytic protein of the Candida ergosterol biosynthesis   pathway Erg11p  lanosterol-14α-demethylase: catalytic protein of the Candida ergosterol    biosynthesis pathway EUCAST  European committee on antimicrobial susceptibility testing ITS   internal transcribed spacer region: DNA sequence that is used to identify    Candida species MALDI-TOF-MS  matrix assisted laser desorption ionization - time of flight - mass     spectrometry: method that can be used to identify Candida species Mdr   multidrug resistance transporter: efflux pump for multiple drug substrates MEGA  molecular evolutionary genetics analysis: software to create phylogenetic trees MIC   minimal inhibitory concentration in µg/ml: specifies antifungal drug    concentration that is needed in order to significantly inhibit the in vitro growth   of microbes ML   Maximum Likelihood: algorithm used to create phylogenetic trees MLST  multilocus sequence typing: sequence-based method to characterize distinct   isolates of the same species 
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NRZMyk  German National Reference Center for Invasive Fungal Infections PCR   polymerase chain reaction: method to amplify small DNA-sequences in vitro RPMI agar  culture media designed specifically for gradient-dependent antifungal    susceptibility tests SNP   single nucleotide polymorphism: variable site in an otherwise conserved DNA   sequence ST   sequence type: used to describe sequence variants of MLST-relevant gene loci,   also called allele (refers only to one locus, a combination of sequence types   from several loci yields a DST) UPGMA  unweighted pair group method wit arithmetic mean: algorithm used to create   phylogenetic trees YPD   yeast extract peptone dextrose medium: culture medium for Candida, used   either as liquid broth or solid agar  Genes: AAT1 - aspartate amino transferase, housekeeping gene used for MLST analysis ACC1 - acetyl-coenzyme A carboxylase, housekeeping gene used for MLST analysis ADP1 - ATP-dependent permease, housekeeping gene used for MLST analysis ERG3 - C-5 sterol desaturase: gene of the Candida ergosterol biosynthesis pathway ERG11 - lanosterol-14α-demethylase: gene of the Candida ergosterol biosynthesis pathway FKS - essential β-1,3-glucan synthase subunit, gene that plays an important role in echinocandin resistance MAT1α - regulator of the α mating type; gene of the MTLα (Mating Type Like) locus: determines the mating type of a Candida isolate MPI - mannose phosphate isomerase, housekeeping gene used for MLST analysis SYA1 - alanyl-RNA synthetase, housekeeping gene used for MLST analysis UPC2 - zinc finger transcription factor, regulator of genes from the ergosterol biosynthesis pathway in Candida VPS13 - vacuolar sorting protein, housekeeping gene used for MLST analysis ZWF1 - glucose-6-phosphate dehydrogenase , housekeeping gene used for MLST analysis  
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1 Zusammenfassung Bakterielle Infektionen sind nach wie vor die Hauptursache für Sepsis. Seit den neunziger Jahren hat jedoch die Zahl der Pilzinfektionen erheblich zugenommen. Systemische fungale Infektionen sind als Krankheitsursache gerade deshalb interessant, weil die Erreger meist endogene Kommensalen des Wirts sind. Candida-Spezies sind ein typisches Beispiel für einen solchen Infektionsverlauf. Von Bedeutung sind vor allem Candida albicans und Candida glabrata, sie werden im Schnitt weltweit in etwa 5-20% aller Blutkulturen nachgewiesen. Diese Dissertation beschäftigt sich mit Candida-Isolaten, die zwischen 2005 und 2012 aus Blutkulturen von Patienten des Universitätsklinikums Würzburg kultiviert wurden. Im Rahmen des Projektes erfolgte eine detaillierte phänotypische und molekulare Charakterisierung der 99 Isolate. Die Candida-Isolate wurden hinsichtlich Spezieszugehörigkeit, individueller genetischer Variabilität und Suszeptibilität gegenüber üblichen antifungalen Wirkstoffen untersucht. Die resultierende individuelle Charakterisierung jedes Isolats wurde für weiterführende epidemiologische und phylogenetische Analysen genutzt.  Distinktive und untereinander vergleichbare genotypische Profile der isolierten Candida albicans – Stämme wurden mit Hilfe von Multilocus Sequenztypisierung (MLST) erstellt. Basiert auf Einzelnukleotidpolymorphismen in konservierten DNA-Abschnitten werden den Isolaten individuelle diploide Sequenztypen zugeordnet. Diese Sequenzprofile können mit Hilfe einer internationalen Datenbank verglichen und zu phylogenetischen Analysen herangezogen werden können. Bei Isolaten, die während der MLST-Analyse experimentelle Probleme verursachten, wurde die Spezieszugehörigkeit überprüft. Dazu wurden Hyphenformation in Flüssigkultur und Wachstumsphänotyp auf CHROM-Agar untersucht. In einigen Fällen wurde zur Absicherung eine ITS-PCR (Amplifikation eines speziestypischen DNA-Bereichs) durchgeführt. Die genotypische Feintypisierung ergab für 95 Isolate ein individuelles MLST-Profil, welches zur Online-Datenbank hinzugefügt werden konnte. Dabei wies die Mehrheit der C. albicans Isolate (75 Stämme) einen zuvor noch nicht beschriebenen Sequenztyp auf. Drei Isolate wurden als C. dubliniensis identifiziert und von weiteren Analysen ausgeschlossen. Zwei Proben wurden als Mischkulturen aus C. albicans und C. glabrata erkannt, wobei es nur bei einem Isolat möglich war, die C. albicans-Komponente zu isolieren und zu analysieren. 
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Eine auf den MLST-Profilen basierte phylogenetische Analyse der C. albicans Isolate mit Hilfe des eBurst-Algorithmus ergab keinen Hinweis auf eindeutige phylogenetische Korrelationen.  Trotz der engen geographischen Limitation und ihres klinisch ähnlichen Ursprungs (Blutkultur) wiesen die Isolate eine große genetische Varianz auf. Bei C. albicans Isolaten mit identischen Sequenztypen wurden im Hinblick auf nosokomiale Transmission die entsprechenden Patientendaten eingesehen. Zum einen wurde somit die Konstanz des Sequenztypen bei subsequenten Isolaten von einem Patienten bestätigt, zum anderen wurde eine Sequenztyp-Gleichheit bei Isolaten von neugeborenen Zwillingen auf der Neonatal-Station festgestellt. In allen anderen Fällen bestand keine nachweisbare räumliche oder zeitliche Verbindung zwischen Patienten, bei denen genetisch weitgehend identische C. albicans Stämme in der Blutkultur auftraten, die Wiederholung des Sequenztyps wurde deshalb als rein zufällig angesehen. Resistenztests für  die antifungalen Wirkstoffe Amphotericin B, Caspofungin, Fluconazol, Itraconazol, Posaconazol und Voriconazol wurden nach standardisierten E-Test-Richtlinien durchgeführt. Unter den 95 getesteten Isolaten wurden größtenteils keine signifikanten Resistenzen gegen die genannten Wirkstoffe festgestellt. Insgesamt konnten im Verlauf dieses Dissertationsprojektes die analysierten Candida-Blutkulturisolate durch MLST-Profile und Suszeptibilitätstests detailliert charakterisiert werden. Die Ergebnisse der genotypischen Analyse zeigen den hohen Stellenwert der MLST bei der Nachverfolgung nosokomialer Transmissionsrouten und bei epidemiologischen Betrachtungen. Die erhaltenen Daten stellen eine wichtige Grundlage für weitere Experimente mit den klinischen Isolaten dar.        
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2 Introduction Next to a variety of bacteria and archeae, fungi are a common part of the normal microbial flora on human mucosal surfaces (Rajilic-Stojanovic und de Vos 2014). Recent studies of the resident microbiota in the human gastrointestinal tract revealed that as much as 66 fungal genera can be present in healthy individuals (Mukherjee et al. 2015). The majority of those intestinal fungi are yeasts, Candida spp. being the most prevalent (Rajilic-Stojanovic und de Vos 2014). Candida species of clinical significance as commensals and opportunistic pathogens of the human host are C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. dubliniensis and C. rugosa (Rajilic-Stojanovic und de Vos 2014, McManus und Coleman 2014). C. albicans is the predominant and clinically most relevant of the mentioned species  (McManus und Coleman 2014). As the major cause of systemic candidiasis, it is regarded as the most pathogenic Candida species that colonizes human hosts (Moran et al. 2004). One explanation for its frequent role as a pathogen might be its high prevalence. C. albicans is established in the gastrointestinal mycobiota very early. The species can be detected in over 95% of one-month-old infants, illustrating how commonly it colonizes the body without causing diseases (Kumamoto und Vinces 2005). Yet as soon as opportunity arises, the harmless commensal is able to act as a pathogen. If the host’s immune system is compromised, the indigenous C. albicans population can cause infections ranging from a superficial mucosal thrush to an invasive, life-threatening candidiasis (Kumamoto und Vinces 2005). Its success as a pathogen is strongly supported by the polymorphic phenotype of C. albicans, which grows as yeast as well as in a filamentous form (McManus und Coleman 2014). As one of only two Candida species that is capable of forming true hyphae (figure 1), C. albicans has considerable advantage during adhesion and tissue invasion, crucial processes during infection (Kumamoto und Vinces 2005, Stokes et al. 2007). Dissemination of Candida in the bloodstream, known as invasive candidiasis or candidemia, is a life-threatening condition. The frequency of nosocomial systemic Candida infections has been increased significantly during the last decades (Colombo et al. 2014, Mikulska et al. 2012). Candidemia was diagnosed with an incidence of 6.9/1000 patients in ICUs worldwide (Kett et al. 2011), which appears to be relatively low. Nevertheless, Wisplinhoff et al found Candida spp. to be the fourth leading cause (9%) of bloodstream infections in hospitalized patients in the US (Wisplinghoff et al. 2004). Interestingly, those Candida-associated bloodstream infections showed the highest crude mortality (39.2%) in the mentioned study (Wisplinghoff et al. 2004). Systemic candidiasis is frequently fatal, especially if the infection causes a systemic inflammatory response syndrome or sepsis. The mortality rate of 
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nosocomial candidemia is generally estimated between 30-60% (Kett et al. 2011, Bougnoux et al. 2008, Gudlaugsson et al. 2003). At risk for a disseminated Candida infection are all hospitalized patients with considerable immune deficiencies. Typical risk factors among ICU patients are long-term antibiotic treatment, solid tumors, cancer chemotherapy, persisting intravascular catheters and organ transplantation attended by medical immune suppression (Giri und Kindo 2012).  Candidemia is not a problem exclusively encountered in the ICU; it is also a condition that affects multi-morbid patients in internal medicine wards with increasing frequency (Mikulska et al. 2012). Old age, parental nutrition and bacterial infections are typical comorbidities in this group (Bassetti et al. 2011).  
  Figure 1: Candida albicans phenotype. Filamentous (hyphae) and planctonic (yeast) growth mode of C. albicans. The transition facilitates adhesion and tissue invasion during a systemic infection and is considered to be one of the central pathogenity mechanism of C. albicans . Microscopic images were taken at the ZIK Septomics facility Jena. Despite continuous improvements of diagnostic methods, prophylaxis and therapy timing, successful treatment of candidemia remains challenging (Mikulska et al. 2012). Although the proportion of bloodstream infections caused by other, sometimes intrinsically resistant Candida species increased recently, C. albicans still remains the leading cause of fungemia (Mikulska et al. 2012, Kett et al. 2011). Next to clinical efforts to decrease candidemia mortality, lab-side analysis of isolated C. albicans strains is important to understand epidemiology, nosocomial transmission routes and development of resistances (Odds und Jacobsen 2008). With the increasing incidence of nosocomial candidemia episodes, several efforts of molecular strain typing were made during the last decades (Lyon et al. 2010). As a diploid 
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organism with a high degree of genome plasticity, C. albicans posed certain challenges to the accuracy of sequence-based typing methods (McManus und Coleman 2014). Clinical isolates were found to exhibit significant karyotype variability (Chibana et al. 2000), which might be owed to C. albicans´ high tolerance of chromosomal rearrangements and even ploidy changes (McManus und Coleman 2014). The predominantly clonal reproduction cycle can be supplemented by a parasexual mating mechanism during times of environmental stress (Forche et al. 2009). The initially tetraploid offspring of this mating undergoes subsequent chromosome loss until the diploid state is reaccomplished (Bennett und Johnson 2003). The absence of a true meiosis process allows the high karyotypic variation observed in C. albicans, for major chromosomal rearrangements are not fatal for the offspring (Chibana et al. 2000). Even loss of heterozygosity and aneuploidy occur frequently and are tolerated well (McManus und Coleman 2014). This genomic plasticity enables C. albicans strains to undergo genetic microvariations during host colonization, infection and through strain transmission (Bougnoux et al. 2006).  Commensal strains are maintained by the host over long periods of time and are often the endogenous source of arising infections (McManus und Coleman 2014). Even so, it is important to employ suitable molecular typing systems to enhance the understanding of the population dynamics of the pathogen and to discover possible origins of nosocomial infections and drug-resistant strains (Lyon et al. 2010). A proper typing system facilitates the assignment of isolates to clades or clusters of a suspected founding genotype and its offspring, which is an essential tool for phylogenetic analysis (Lyon et al. 2010). Before the widespread use of molecular typing techniques, efforts were made to classify C. albicans isolates phenotypically (McManus und Coleman 2014). But methods like serotyping, morphotyping and antimicrobial agent susceptibility testing lacked discriminatory power and reproducibility (McManus und Coleman 2014). Although multi-locus enzyme electrophoresis (MLEE) was a more reliable phenotypic typing method, it was not sufficiently able to detect small genetic variations (Saghrouni et al. 2013). Prior to the common availability and affordability of DNA sequencing, molecular typing methods targeted alterations in restriction endonuclease cleavage sites (McManus und Coleman 2014). The major disadvantage of DNA-based, non-sequencing typing methods like restriction fragment length polymorphism (RFLP), randomly amplified polymorphic DNA (RAPD) and electrophoretic karyotyping (EK) is that results are laboratory dependent (Bougnoux et al. 2002). A combination of restriction endonuclease digestion and southern blot hybridization, the Ca3 fingerprinting probe, is the non-sequence based typing method with the highest discriminatory power 
 11 
(0.993) (Robles et al. 2004). This method is hold as reproducible and serviceable for computer-assisted phylogenetic analysis (Lyon et al. 2010). Isolates analyzed with Ca3 fingerprinting could be assigned to three distinct, geographically widespread clades that are still viable today (Robles et al. 2004). Two additional clades showed a geographical enrichment for Southern Africa and Europe (the SA and E clades) (McManus und Coleman 2014). Despite those promising features, Ca3 fingerprint analysis did not establish itself as the predominant molecular typing method, mainly because it is time-consuming, technically demanding and the results can not be easily compared or shared between different laboratories (McManus und Coleman 2014). The gold standard of molecular typing is based on the direct analysis of DNA sequences. Multilocus sequence typing (MLST) relies on the PCR amplification and DNA sequencing of seven highly conserved DNA sections (Bougnoux et al. 2002). MLST fulfills all requirements for an effective molecular typing system (McManus und Coleman 2014). Its resolution is sufficiently high to discriminate closely related strains as individual genotypes and to recognize identical strains in a sample of isolates (Bougnoux et al. 2002). MLST has a discriminatory power of 0.999, thus having a better resolution than Ca3 fingerprinting (McManus und Coleman 2014). The major advantage of the molecular typing assay over the Ca3 fingerprinting system is the high reproducibility and easy conduction of MLST (Tavanti et al. 2003). Subjectivity in data interpretation and inter-laboratory differences are negligible, thereby yielding a data output that can be shared and compared between different labs (Bougnoux et al. 2004). A serviceable typing system should be able to reflect only evolutionary genomic changes and neglect unstable variations that are the result of a high genomic plasticity (McManus und Coleman 2014). MLST is applied to C. albicans loci that are under stabilizing selection pressure, consequently delivering results that meet the contemplated demands (Tavanti et al. 2003). MLST data are utilizable for software-assisted phylogenetic analysis and it is possible to estimate the genetic distance between related isolates employing the MLST results (Odds et al. 2007). The last specific advantage of MLST in regard to C. albicans is that the system is serviceable for permanently diploid organisms. In reviewing the sequencing chromatograms of an MLST-locus, determination and identification of different nucleotides in heterozygous positions is possible (Odds und Jacobsen 2008). Multilocus-sequence typing of C. albicans is based on sequence variations in 400-500bp fragments of seven housekeeping loci. Bougnoux and Tavanti et al. proposed a set of primers for the amplification of the seven genes that achieved universal acceptance (table 1) (Bougnoux et al. 2002, Tavanti et al. 2003). Some of those specific housekeeping gene 
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regions were chosen because of their high divergence from corresponding regions in the Saccharomyces cerevisiae ortholog (Bougnoux et al. 2002). Several loci encode highly polymorphic proteins that were already used in multilocus enzyme electrophoresis typing assays (Tavanti et al. 2003). All seven loci contain multiple variable sites and thereby hold a high discriminatory power, but are evolutionary conserved and under stabilizing selection pressure at the same time (Bougnoux et al. 2002). The variable sites that are of interest for MLST are single nucleotide polymorphisms (SNPs). Each locus contains 7 (ACC1) to 17 (VPS13) SNPs (see table 1) (Bougnoux et al. 2003). Local heterozygosity is frequent in those gene fragments, so the MLST data often show two different nucleotides in one variable position. The PCR primers (see table 1) amplify both alleles from homologous chromosomes in case of heterozygosity (Tavanti et al. 2003). The sequence chromatogram then shows two overlapping peaks of equal height, indicating the presence of both nucleotides in this diploid variable position (Odds und Jacobsen 2008). The individual combination of nucleotides in the variable positions of one locus is defined as a genotype (the term “allele” is commonly used, too) (Bougnoux et al. 2002). All heterozygous variable positions are taken into account during the sequence analysis (Odds und Jacobsen 2008). Each genotype is numbered in the order of identification (Bougnoux et al. 2002).  Table 1. Summary of loci used for C. albicans MLST with current number of genotypes found for each locus (Tavanti et al. 2003, Bougnoux et al. 2003, http://calbicans.mlst.net/misc/info.asp, http://pubmlst.org/calbicans/)  Locus Gene Primer seq. size (bp) No. of SNPs No. of geno-types AAT1a Aspartate Amino-transferase Fwd 5’-ACTCAAGCTAGATTTTTGGC- 3’ Rev 5’-CAGCAACATGATTAGCCC- 3’  349 10 159 ACC1 Acetyl-coenzyme A carboxylase Fwd 5’-GCAAGAGAAATTTTAATTCAATG- 3’ Rev 5’-TTCATCAACATCATCCAAGTG- 3’  407 7 106 ADP1 ATP-dependent permease Fwd 5’-GAGCCAAGTATGAATGATTTG- 3’ Rev 5’-TTGATCAACAAACCCGATAAT- 3’  443 16 146 MPIb Mannose phosphate Fwd 5’-ACCAGAAATGGCCATTGC- 3’ 375 11 155 
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isomerase Rev 5’-GCAGCCATGCATTCAATTAT- 3’  SYA1 Alanyl-RNA synthetase Fwd 5’-AGAAGAATTGTTGCTGTTACTG- 3’ Rev 5’-GTTACCTTTACCACCAGCTTT- 3’  391 13 207 VPS13 vacuolar protein sorting protein Fwd 5’-TCGTTGAGAGATATTCGACTT- 3’ Rev 5’-ACGGATGGATCTCCAGTCC- 3’  403 17 280 ZWF1b Glucose-6-phosphate dehydrogenase Fwd 5’-GTTTCATTTGATCCTGAAGC- 3’ Rev 5’-GCCATTGATAAGTACCTGGAT- 3’  491 9 267  The total of seven individual genotypes is then combined to a distinct diploid sequence type (DST), which obtains a number, too (Bougnoux et al. 2002). All genotypes and diploid sequence types are registered and curated in a publicly available online database (http://pubmlst.org/calbicans/). The allelic variations in those seven relatively small DNA fragments provide sufficient information to describe clinical C. albicans isolates with high discriminatory power (Bougnoux et al. 2002). Through the online database it is possible to compare origins, prevalence and phylogeny of isolates internationally (Bougnoux et al. 2004). Phylogenetic trees are an expression of the reconstructed evolutionary history of an organism. Whilst it is possible for animals and plants to build phylogenetic trees using comparative morphology and physiology and the support of fossil records, this method is insufficient for microbes (Nei und Kumar 2000). A more timely approach to study evolutionary relationships, even of the smallest organisms, is the molecular phylogenetic comparison of DNA sequences (Nei und Kumar 2000). A phylogenetic tree is able to represent estimated relationships between any kind of homologous DNA or protein sequences and their hypothetical common ancestors (Hall 2013). Thereby the molecular phylogenetic approach can avoid controversial systematic classifications like species, genera and taxa assignments (Nei und Kumar 2000). Suitable software, such as MEGA and eBurst, facilitates sequence-based phylogenetic analysis. There are several widely-accepted methods to estimate a phylogenetic tree from molecular data, for example Neighbor Joining, UPGMA/Maximum Parsimony, Bayesian Interference and Maximum Likelihood (ML) (Hall 2013). They are all based on the analysis of aligned homologous sequences; in case of C. albicans MLST analysis, the sequences of the 
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complex” around the predicted group founder (Figure 2) (Spratt et al. 2004). In application to MLST data, a clonal complex is formed from diploid sequence types that differ in only one or two alleles. The mutually exclusive groups are structured as a radial diagram with the predicted founding genotype in the center, expressing the hypothetical pattern of sequence diversification (Spratt et al. 2004). Irrespective of the algorithm that is used to analyze MLST data, the formation of groups and clades is supposed to be relatively consistent (McManus und Coleman 2014). Odds et al. analyzed a large proportion of the C. albicans MLST database using MEGA and eBurst and defined 17 clades and 53 clonal clusters (Odds et al. 2007). The clades determined in a UPGMA dendrogram correlate well with clonal clusters from the eBurst analysis. Clonal clusters respect the clade boundaries, whereas clades can contain more than one clonal cluster (Odds und Jacobsen 2008). Clade 1 and respectively clonal cluster 1 are usually the largest specified groups of the phylogenetic analysis (Odds et al. 2007). The most common DST in this group is DST 69 (Odds et al. 2007). The clades 1-4 contain with ~67% of the analyzed DSTs the major proportion of the C. albicans isolates (Odds et al. 2007). Those clades fully correspond to the previously described clade assignments from Ca3 DNA fingerprinting, clades I, II, III and SA, respectively (Odds et al. 2007). A univariate ANOVA was used to identify specific strain characteristics that are associated with clade designations in a statistically significant way (Odds et al. 2007). The analysis showed that only ABC type and geographical origin of the isolates were highly significant in relation to clade assignment (Odds et al. 2007). Mating type, time of isolation, anatomical origin and drug susceptibility did not show a significant correlation with the clade designation (Odds et al. 2007). Although a differential distribution of pathogenic and commensal isolates and of anatomical origins was observed to some extent, statistically significant clade distributions were not proven (McManus und Coleman 2014). Reduced susceptibility to azole antifungal agents was found in a low percentage of the isolates analyzed by Odds et al. (Odds et al. 2007). While the prevalence of those isolates in some clades (clades 5 and 6 and singletons) was subjectively higher than expected, there was no significant correlation between antifungal susceptibility and clade distribution (Odds et al. 2007). An enrichment of isolates with low flucytosine susceptibility in clade 1 was the only observation that could be proven to be statistically significant (Odds et al. 2007). These data correspond with former studies that assumed a restriction of genetic flucytosine resistance to Ca3 fingerprinting group I (Pujol et al. 2004). With respect to recombination events, blurring of geographical effects by 
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global travel and the influence of genes that are not considered in MLST analysis (Odds und Jacobsen 2008), all studies of clade-associated properties should be carefully reflected. Resistance of Candida spp. to antifungal drugs poses an emerging problem in the treatment of patients with invasive fungal diseases, possibly leading to clinical failures (Maubon et al. 2014). Despite the availability of new and improved antifungal drugs, the mortality rates of patients with invasive candidiasis are still critically high (Alcazar-Fuoli und Mellado 2014). While the outcome of a serious bloodstream infection depends mainly on the status of the host, fast diagnosis of fungemia and a prompt antifungal treatment can have a major impact (Alcazar-Fuoli und Mellado 2014). The demand for an appropriate and speedy response to invasive fungal diseases constitutes a complex challenge. If the response of the clinical isolate to the chosen antifungal is poor, the result might be fatal (Pfaller 2012, Pfaller und Castanheira 2016). The seriousness of invasive candidiasis and the difficulties in prompt diagnosis increasingly lead to prophylactic and empirical use of antifungal drugs in high-risk patients and cases of persisting infections (Alcazar-Fuoli und Mellado 2014). The liberate application of antifungal therapy induces a problematic selective pressure in favor of antifungal resistances (Alcazar-Fuoli und Mellado 2014). Although resistance mechanism and their distribution are not as pronounced in fungi as in prokaryotes, insensitivity to antifungal drugs is a serious threat and should be a focus in the analysis of clinical isolates (Arendrup 2013, Lockhart et al. 2012). The need for well-tolerated, host-compatible drugs limits the number of targets that can be affected by antifungal agents (Odds et al. 2003). Currently, three classes of antifungals are commonly used: triazoles, echinocandins and polyenes (Alcazar-Fuoli und Mellado 2014). Their action mechanisms are molecularly different, but usually interfere with the integrity of the fungal cell wall and membrane (Maubon et al. 2014). Additionally, there are some less popular antifungal agents like base analogues (e.g. flucytosine) and others available (Odds et al. 2003). Triazoles like fluconazole, itraconazole and the newer broad-spectrum variants voriconazole and posaconazole are the largest class of antifungal agents (Odds et al. 2003, Maubon et al. 2014). Those very commonly applied drugs inhibit the synthesis of the main component of the fungal cell membrane, ergosterol (Terrell 1999). Targeting a catalytic protein from the ergosterol synthesis pathway, the lanosterol-14α-demethylase (also known as Cyp51p in Aspergillus spp. and Erg11p in Candida spp.), triazoles lead to ergosterol depletion in the fungal membrane (Figure 3) (Odds et al. 2003). Subsequently, membrane permeability and fluidity is altered and the activity of membrane-bound proteins is changed (Odds et al. 2003). 
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membrane, causing pore formation and ion leakage (Alcazar-Fuoli und Mellado 2014). Polyene drugs can cause serious side effects due to binding to human membrane sterols (Kotler-Brajtburg et al. 1974), therefore triazoles and echinocandins are more common for systemic application nowadays (Odds et al. 2003).  Resistance to antifungal drugs can be defined in two categories (www.eucast.org, (Alcazar-Fuoli und Mellado 2014). Microbiological resistance is defined by the presence of an acquired or intrinsic resistance mechanism in an isolate (Alcazar-Fuoli und Mellado 2014). This state can either be innate (primary resistance) or acquired secondary in response to drug exposure (Alcazar-Fuoli und Mellado 2014). In an antifungal susceptibility test, any isolate is either categorized as susceptible, intermediate or resistant to a certain drug (www.eucast.org). In vitro resistance is determined by defined clinical breakpoints and is likely associated with therapeutic failures if the drug choice is not adapted to the resistance pattern. Resistance can be achieved through different mechanisms. One general mechanism that heightens the tolerance against antifungal agents and can lead to clinical resistance is biofilm formation (Pfaller und Riley 1992). It was observed that yeast cells in biofilms are up to a 1000 times more tolerant against azoles than their planctonic counterparts (Lamfon et al. 2004). This phenomenon is a result of a combination of various single aspects. Biofilm formation is associated with Efflux-pump up-regulation, a changed sterole composition of the membrane and activation of general stress responses (Taff et al. 2013). Additionally, the penetration of antifungal drugs into the biofilm is inhibited by the presence of an extracellular matrix (Mitchell et al. 2013). Irrespective of the presence of a biofilm, cellular stress responses like an elevated cell wall chitin content can generally lead to a resistance to antifungal treatment (Maubon et al. 2014). Other resistance mechanisms are limited to certain classes of antifungal agents. Resistance against azole drugs can be achieved through three basic mechanisms, which can operate simultaneously by sequential acquisition (Alcazar-Fuoli und Mellado 2014, Maubon et al. 2014). Firstly, an induction of efflux pumps like Cdr1, Cdr2 and Mdr affects all azole drugs by decreasing the intracellular drug concentration (Kanafani und Perfect 2008). Upregulation of the Mdr transporter especially affects fluconazole treatment (Pfaller 2012). The second way to achieve azole resistance is modulation of the target enzyme Erg11p (Li et al. 2004). Azole affinity to the lanosterol-14α-demethylase can be decreased due to multiple point mutations in the ERG11 gene (Marichal et al. 1999). If the structure of the target enzyme itself is unchanged, a gain-of-function mutation in the transcription factor UPC2 may lead to a 
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considerable overexpression of Erg11p, thereby promoting clinical azole resistance (Flowers et al. 2012). Finally, ERG3 mutations can offer a metabolic bypass to secure membrane integrity by fecosterole synthesis, leading to a reduced effect of azole treatment (Morio et al. 2012). Reduced susceptibility particularly to echinocandin drugs is mostly caused by mutations in the FKS gene, either intrinsic (Barchiesi et al. 2006) or acquired (Beyda et al. 2012). Resistance mechanisms specifically affecting polyene drugs are rare and mostly associated with mutations in the ERG3 gene which lead to ergosterole depletion in the membrane (Morio et al. 2012). Although resistances in Candida spp. are still rare (Arendrup 2013), the increasing number of fungal infections and the more excessive use of antifungal drugs make a standardized and reliable antifungal susceptibility testing necessary (Pfaller und Diekema 2012). The Clinical and Laboratory Standard Institute (CLSI) and the EUCAST established standardized antifungal susceptibility testing methods (broth microdilution or commercially available E-test stripes) (Alcazar-Fuoli und Mellado 2014). The ultimate result of these tests is the minimal inhibitory concentration (MIC) of an antifungal agent for each Candida spp. isolate (Espinel-Ingroff et al. 2014). Based on the analysis of several MICs from wild-type isolates, the EUCAST committee defined epidemiological cutoff values (ECVs/ECOFFs) (http://www.eucast.org/clinical_breakpoints/). The ECV sets the highest susceptibility endpoint of a wild type-population MIC, thereby assisting the detection of an in vitro resistance (Espinel-Ingroff et al. 2014). While ECVs are argued to be inexpedient, there is a more practical approach combining laboratory and clinical data (Arendrup 2013). CLSI and EUCAST ventured to predict the likelihood of an isolate to be clinically resistant by defining clinical breakpoints (CBP), which correlate with the in vitro MICs (Alcazar-Fuoli und Mellado 2014). In conclusion, standardized antifungal susceptibility testing provides important information about a set of isolates. Even if the susceptibility testing is not directly related to a clinical treatment recommendation, the data provide valuable information considering cutoff- and breakpoint value setting (Alcazar-Fuoli und Mellado 2014). Standardized testing can be useful in the development of faster and therefore clinically more relevant methods (Alcazar-Fuoli und Mellado 2014). Detection of in vitro resistance is important for better understanding and avoidance of resistance mechanisms (Alcazar-Fuoli und Mellado 2014).  
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3 Aims of the project This research project was conducted in the fungal Septomics group of the ZIK Septomics in cooperation with the NRZMyk Jena. In context of the scientific analysis of the pathology of Candida bloodstream infections, it is important to take a close look at the variation of clinical isolates. The main intention of this venture was to provide a genotypically and phenotypically well characterized collection of clinical Candida albicans isolates. This strain compilation will be available for further research concerning host-pathogen interaction. It can be utilized to analyze intra-species variations in immune recognition and response triggering in a full-blood model. Each Candida albicans isolate was profiled using MLST, subsequently adding internationally available strain information to the MLST-online database. This part of the project was conducted in cooperation with the current curator of the database, M.-E. Bougnoux (Bougnoux et al. 2002).  Genotype profiles of the C. albicans strain collection were phylogenetically reviewed to get insight in the variability of isolates from a geographically limited area. In addition, patient data were surveyed to assess the likelihood of nosocomial transmission of Candida strains. Additionally, the research did offer an insight in the accuracy of species identification in clinical isolates. Awareness of the quality standard of routine, hospital-associated lab work provides a possibility for refinement. Species identification, genotypic characterization and resistance profiling of isolates can be improved by taking advantage of the advanced standards of a reference lab like the NRZMyk. Another aim of this project was the analysis of the antifungal susceptibility and of the incidence of resistance to antifungal agents in the set of clinical C. albicans isolates in cooperation with the NRZMyk. The frequency of resistant strains, combined with patient data such as severity of the illness and clinical outcome, could provide interesting information concerning epidemiology and treatment recommendations (Pfaller 2012).    
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4 Results: Original publication 
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5 Discussion The collection of 99 clinical Candida isolates could be phylogenetically characterized in depth during the project. It was possible to explicitly determine the species of each isolate: as expected, the major section of the collection consists of C. albicans isolates (95 samples). Those strains could be unambiguously defined genotypically using a sequence-based method. Additionally, antifungal susceptibility properties were adjoined to the individual characterization of each strain. The detailed strain delineation that was achieved using the MLST method is essential for the subsequent phylogenetic analysis of the strain compilation and for the review of patient data concerning potential nosocomial transmission. Furthermore, genotypic specification and the following phylogenetic classification of the isolates are necessary groundwork for future research concerning virulence and immune-response variations. Virulence properties depending on phenotyping switching, adhesion, biofilm formation and hydrolytic enzyme production may differ considerable between individual C. albicans isolates (Bliss et al. 2012). An enhanced virulence may facilitate the transition from a commensal to an invasive growing isolate (Bliss et al. 2012). Additionally, different invasive isolates of the same species may possibly trigger explicitly different immune reactions under standardized conditions (Toth et al. 2015). Immune recognition may vary between different clinical strains, thereby stimulating a host response of distinct quality and intensity, which will in turn influence growth and phenotype of the pathogen (Marakalala et al. 2013). The dynamics of this host-pathogen-interaction and the influence of genetic micro-variations on the virulence of isolates from a single species are interesting and complex to study. The classifications that were made during this project may contribute a part to this research. Multilocus sequence typing has proven to be a useful and reliable method for the purposes of this project. In confirmation of the commonly published opinion, we evaluated MLST as an easily conducted, objective and reproducible method with sound and reliable results (Bougnoux et al. 2002). The high quality and reproducibility of this method could be proven during the analysis of the strain collection from Würzburg. The inclusion of three sequential isolates from a single patient served as an internal control of the procedure. Those samples were unequivocally classified as identical, which confirms the eligibility of MLST to analyze clinical isolates. Two other strains with identical DSTs could be retraced to originate from newborn twins, making perinatal transmission from the mother a probable explanation for the congruence. Those results also show that the analyzed DNA fragments are stable enough to 
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positively identify a strain through the course of infection and transmission, eliminating doubts about the influence of genetic micro-evolution on the certainty of strain recognition (Reiss et al. 1998, Bougnoux et al. 2002). In summary, MLST was estimated as a highly qualified method of distinction for C. albicans isolates during this project. Nosocomial transmission of fungal infections is occasionally mentioned in literature (Pfaller 1996), but cases of horizontal transmission of C. albicans infections are seldom and not easily proven. In accordance with this, our review of the patient data belonging to isolates with identical DSTs did not reveal an evident connection between the infected patients. On these grounds, we consider a nosocomial transmission leading to C. albicans infections as highly unlikely in question of the analyzed strain collection from Würzburg. The main source for systemic Candida infections is endogenous colonization, strains that are maintained by the host over prolonged periods of time before the infection arises (Verduyn Lunel et al. 1999). Nevertheless, there are possibilities to acquire a Candida infection from a nosocomial environment, e.g. transfer by health care workers or contaminated biomaterials and medical devices (Pfaller 1996, Verduyn Lunel et al. 1999). In these cases, MLST would be a probate and highly qualified method to identify nosocomial infections and, possibly, the transmission routes (Marcos-Zambrano et al. 2014, Hammarskjold et al. 2013). In terms of phylogenetic analysis, MLST provides an opportunity to find similarities between different C. albicans isolates (Odds et al. 2007). Nowadays, phylogenetic trees can be used to study the evolutionary and epidemiological development of pathogenic species and populations (Yang und Rannala 2012). MLST data can be used to create gene trees, which are built from fragments of homologous genomic DNA from different individuals (Szollosi et al. 2015). The information that this kind of tree is supposed to contain is the evolution of one or more homologous genes – with a theoretical ancestral copy of said gene as a start point, nodes as recombination or mutation events and the branches representing the persistent replication of this sequence copy over time (Yang und Rannala 2012). Therefore, gene trees reflect the genealogy of genomic DNA, which is not equal to the development of a species. In fact, gene trees are more informative if they contain orthologous genes from different species and reach over several specification events (Szollosi et al. 2015). A phylogenetic tree made from MLST data only gained from C. albicans bloodstream isolates is a very limited form of a gene tree.  It is restricted to homologous sequence fragments of a certain species that were chosen for analysis due to their evolutionary stability. Such a tree is not able to reflect on species diversification or even the development of a gene through duplication, transposition, loss or 
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horizontal transfer (Szollosi et al. 2015). The only information that is contained in an MLST-gene tree is the variation of polymorphic sites in the sequence, which might occur due to point mutations, insertions or deletions. The existence and recombination of different alleles in diploid species further obscures the evolutionary dynamics. Those kind of trees are hold as highly uncertain, a fact that is supported by the big variety of trees that can be constructed from a single dataset, depending on the algorithm that was used (Yang und Rannala 2012). MLST data are often used to create phylogenetic trees, which are in turn interpreted to separate the contained individuals in multiple clades (Glaeser und Kampfer 2015). This approach might be valuable to get an overview of the genomic variability and relatedness of isolates. But due to the restrictions and incongruence of such a tree it should be kept in mind that it can only give information about the relative distance between single isolates, but is not able to place them definitely at one branch of the tree (respectively in a certain clade) or reflect on its evolution. Besides, the sequence fragments used for an MLST analysis are convenient, but may not be representative for the genome in its entirety (Chaudhuri und Henderson 2012). Summarized, an MLST tree contains, due to sequence choice and the number of isolates, too little information to make a reliable assessment about the evolution of its members. Due to this assessment and multiple failed attempts to produce a congruent tree with the 95 C. albicans MLST-profiles, we decided to abstain from offering a definite result of our molecular phylogenetic analysis. Even so, the MLST data provided valuable information concerning the high genetic variability of the isolate collection. As confirmation, an eBURST analysis including all DSTs of the C. albicans MLST database was sufficiently able to display the heterogeneous distribution of the analyzed strains among multiple clonal clusters. Against initial expectations, there was no perceptible dominance of certain clades in the isolate collection from the university hospital Würzburg. In a compilation of strains gained only from blood samples and from a geographically very limited area, we would have supposed to discover a grouping of the isolates in few clades or clonal clusters due to their specific characteristics. It was frequently published that characteristics like geographical origin, site of isolation, MAT locus, decade of isolation and susceptibility patterns show noticeable affiliations to the clade number (Odds et al. 2007, Odds und Jacobsen 2008, McManus und Coleman 2014). Interestingly, a significant relation between clade assignment and isolation characteristics could only be proven for geographical traits and mating type (Odds et al. 2007). Since the MAT locus was not analyzed in this study, we concentrated on the geographical enrichments of some clades. For Continental European bloodstream isolates, a clustering of the strains in clade 1, 2, 4, 10 and 11 would have been expected (McManus 
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und Coleman 2014). Those anticipations were not confirmed in the results of the eBurst diagram or the different dendrograms that were produced during the analysis (results not shown). As previously explained, the delineation of clades from a dendrogram is arbitrary and has no clinical background (Odds und Jacobsen 2008). Due to multiple influence factors and blurring by the international interexchange of host populations, the assumption that clade-associated properties might facilitate the phylogenetic mapping of C. albicans isolates should be carefully contemplated. Either the strain compilation of this study is indeed more heterogeneous than expected due to nationality, status and general variability of the patients, which is quite possible in a city with a considerable portion of international students.  Or, due to the mentioned infirmities of phylogenetic analysis, a distinct clade mapping is too uncertain to be reliable. Studies with C. albicans strains isolated from more homogenous populations in a smaller geographical setting and a more tight time period might help to discover if phylogenetic clade assignments do still have geographical correlations. In terms of specific traits of clades and clonal clusters, it would be desirable to include more metadata from single strains into the MLST database. Currently only new DSTs are added to the data content. Prospectively, it would be useful to add information like anatomical source, geographical origin and susceptibility pattern from single isolates to an already registered DST. This could aid future statistical analysis of the correlation between clade assignment and strain characteristics, thereby either enhancing or disproving the rightfulness of this approach. Remarkably, five of the isolates that were identified as C. albicans at the hospital did not or not exclusively contain a C. albicans strain. Three isolates (CABI 6, CABI 11 and CABI 49) were identified as C. dubliniensis during the MLST analysis. This misclassification occurs commonly when standard diagnostic procedures, e.g. growth on CHROMagar, Chlamydospore formation or hyphae formation, are used to discriminate Candida species (Kurzai et al. 2000).  In general, C. dubliniensis shares major phenotypic properties with C. albicans and was only recognized to be a distinct species in 1995 (Sullivan et al. 1995). C. dubliniensis´ prevalence, especially in blood samples, was underestimated due to frequent misidentification (Kurzai et al. 2000). To avoid such failures and to accelerate diagnostic procedures, molecular methods like PCR of the species-specific internal transcribed spacer region (ITS) are recommended (Kurzai et al. 2000). To provide a reliable and fast species identification, molecular diagnostic methods should be conventional. Recently, several other quick identification methods have been established for Candida. For example, peptide nucleic acid (PNA) – fluorescent in situ hybridization (FISH) and a MALDI-TOF-MS approach (Pfaller und Castanheira 2016). Those tests can be applied directly to blood cultures or agar 
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cultures and have the great advantage of timeliness and accuracy (results available 1 to 2 hours post culture), which is crucial for an appropriate treatment (Pfaller und Castanheira 2016). Nevertheless, they are expensive and exceed the means of a routine diagnostic lab concerning technology, conduction and practicability.  Our isolate collection was assembled from 2005-2012. Although species identification was no longer solely relied on conventional, phenotype-based methods during that period of time, some misidentifications have occurred. In case of C. albicans and C. dubliniensis, a confusion of species identity does not have a major impact on the correct and timely application of antifungal therapy. C. dubliniensis is in fact considered to be less pathogenic than C. albicans (Coleman et al. 2010). Most C. dubliniensis isolates are susceptible to antifungal drugs that are commonly used to treat systemic Candida infections (Coleman et al. 2010), therefore the misidentifications that we detected in our strain compilation were of no therapeutical consequence at the time of treatment. Contrary, diagnostic errors in the analysis of a blood culture containing C. glabrata could deteriorate the prognosis of the patient. The susceptibility patterns of C. glabrata are distinctly different than those of C. albicans and C. dubliniensis: Minimal inhibitory concentrations for most antifungals are higher, acquired resistances are more common and the tolerance against azole antifungals is innately high (Turner und Butler 2014, Pfaller und Castanheira 2016). Therefore, therapeutic failures are more likely in case of a C. glabrata infection and an application of echinocandins or polyenes instead of a common triazole therapy is beneficial (Glockner und Cornely 2015, Pfaller und Castanheira 2016). The opportunity to make such a therapeutic decision was lost in one case in our collection of clinical specimens. Among the 99 isolates, we detected two mixed culture containing C. albicans as well as C. glabrata (CABI 8 and CABI 22). A review of the clinical data revealed that only one was recognized as such during the time of isolation. In case of the other mixed culture, the C. glabrata isolate was not identified. However, it can not be excluded that contamination of the original sample occured later during the storage, culture and analysis processes of the strain.  A rapid and sensitive diagnosis of the invasive Candida species can ensure the necessity of antifungal treatment and the timely application of the correctly dosed drug. This is an important precondition considering antifungal stewardship and  the reduction of therapy costs and the still considerable mortality of Candidemia patients (Pfaller und Castanheira 2016).  Susceptibility to fluconazole, itraconazole, voriconazole, posaconalzole, caspofungin, anidulafungin and amphotericin B was tested for all 95 C. albicans isolates following the 
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EUCAST guidelines. We could successfully estimate the in vitro minimal inhibitory concentration (MIC) for each antifungal drug. Using the EUCAST breakpoints, we categorized most isolates as susceptible (six isolates were categorized as resistant to itraconazole, a result which is likely not of clinical relevance and might be owed to methodical difficulties). This kind of susceptibility testing can identify patients at risk of clinical failure. Nevertheless, microbiological or in vitro susceptibility or resistance will not be a reliable predictor of clinical resistance (Maubon et al. 2014). Clinical breakpoints (CBPs) are an attempt to take the clinical outcome, dependent on the virulence of the pathogen and aspects of the host´s health, into account (Maubon et al. 2014). Therefore they provide a slightly better prediction for clinically relevant resistances than the otherwise employed epidemiological cutoff values (ECVs/ECOFFs) (Espinel-Ingroff et al. 2013a). But clinical resistance, defined as a persisting or worsening fungal infection or a breakthrough infection under antifungal therapy, is frequently not caused by a strain with an in vitro resistant phenotype. Rather, the general health or sickness of the patient, organ failures, immune suppression and old age play an important role in the failure of antifungal treatment (Maubon et al. 2014). Pharmacodynamic considerations like biofilm formation or infection of sites where antifungal drugs can not penetrate also have an impact (Taff et al. 2013). Additionally, routine susceptibility tests require the growth of purified cultures and are therefore a slow method, while antifungal therapy is a very time-sensitive matter (Pfaller und Castanheira 2016). Overall, the benefit of susceptibility testing for patient-specific treatment recommendations is limited and the results of in vitro tests should be carefully interpreted (Maubon et al. 2014).  Nevertheless, regular antifungal susceptibility tests are an indispensable tool to establish valuable antifungal treatment recommendations and to monitor emerging resistances (Alcazar-Fuoli und Mellado 2014, Pfaller und Diekema 2012). Constant monitoring of susceptibilities and the setting and refining of species-specific clinical breakpoints provide valuable assistance in the selection of the most promising first-line antifungal therapy (Alcazar-Fuoli und Mellado 2014). Therefore, antifungal susceptibility testing might not always have a direct, case-specific clinical impact, but should not be neglected due to its epidemiological importance. Antifungal susceptibility testing is usually conducted using test systems according to the CLSI standards, for example the commercially available Etest (bioMérieux) or microdiluation assays. The tests mostly rely on isolated fungal cultures, although there are efforts to perform 
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susceptibility tests directly on positive blood cultures in order to accelerate the method (Maubon et al. 2014). The advantage of standardized test systems clearly lies in the opportunity to compare results of different labs considering epidemiological analysis. But next to the fact that they are time-consuming (at least 24 hours before the first results can be estimated), standardized antifungal susceptibility tests are not flawless in their conduction.  
 Figure 4: Exemplary Etest from one of the C. albicans bloodstream isolates from this project. The image shows the main challenges in Etest conduction and evaluation: firstly, the equal distribution and growth of the exact amount of colony forming units (CFUs). Secondly, the correct reading of the end point of the inhibition zone. For the triazoles, the reading is difficult because of the microcultures in the inhibition zone and the phenomenon of trailing end points. For caspofungin and partly for itraconazole, the slender ending of the bottle-shaped inhibition zone makes a clear reading of the end point challenging.  The accurate performance and especially the interpretation of the results of Etests is not indisputable (Figure 4). Firstly, inoculum size and distribution on the agar plate can be a 
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source of error. Secondly, the reading of the MIC result requires some experience and is not always unquestionable (Figure 4). For example, the inhibition zone for triazoles is not colony-free. The occurrence of microcolonies and the phenomenon of trailing end points make the interpretation of the test results difficult (Figure 4). The shape of the inhibition zone itself can also impede the correct reading of the end-point: a drop-shaped inhibition zone is easier to read than a narrow, bottle-shaped one like it is found for itraconazole and caspofungin (Figure 4). This difficulty might explain why six otherwise unobtrusive isolates were classified as resistant against itraconazole according to EUCAST breakpoints. This result might be owed to the difficulties of the method and likely has no clinical impact. In case of caspofungin, the inter-laboratory variations of antifungal susceptibility testing are significant enough to prevent the EUCAST committee from publishing official break points for interpretation (Espinel-Ingroff et al. 2013b)(www.eucast.org). Alternatively, it is recommended to consider isolates which are susceptible to anidulafungin and micafungin as also susceptible to caspofungin (www.eucast.org). Interestingly, we found no correlation between anidulafungin and caspofungin MICs, rendering a similarity in susceptibility patterns questionable. According to current publications, the lack of correlation might be explained with the uncertainty of caspofungin MIC determination rather than with a significant difference in efficacy (Espinel-Ingroff et al. 2013b). It is controversially disputed if routine in vitro testing for caspofungin resistance should be performed at all (Espinel-Ingroff et al. 2013b). Resistance is still an uncommon trait in Candida spp., especially in C. albicans. Some species show an intrinsic resistance, for example C. glabrata and C. krusei have a high tolerance against azoles (Pfaller und Castanheira 2016), while C. parapsilosis is less susceptible against echinocandins due to polymorphisms in the FKS gene (Maubon et al. 2014). For C. albicans, widespread internal resistance mechanisms are highly unusual. But in response to drug exposure, resistance can be acquired through distinct mutations and differential gene expression (Pfaller 2012). Emphasizing the importance of antifungal stewardship, selection pressure through drug exposure is the main reason for the increase of acquired resistances in Candida spp. , which was extensively proven for echinocandin and pan-azole resistance in C. glabrata (Alexander et al. 2013, Pfaller und Castanheira 2016, Maubon et al. 2014) .  Still, C. albicans is considered as unproblematic concerning resistances (Pfaller und Castanheira 2016). Resistance against echinocandins is estimated to occur with a frequency of 
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less than 1% (Pfaller et al. 2013). Azole resistance can be achieved readily through efflux pump induction (Cdr1, Cdr2 and Mdr1) or mutations of the target enzyme (ERG11p) and other enzymes of the sterole metabolism (ERG3p) (Li et al. 2004). But overall, with merely 0.4% azole resistance, C. albicans is not a source for major concerns yet (Pfaller et al. 2013). Polyene, respectively Amphotericin B in vitro resistance, is very rare in all Candida species and therefore has no significant impact (Maubon et al. 2014). Overall, the results of the antifungal susceptibility tests conducted in this project matched the prior expectations. No significant discrepancies or alarming resistance patterns were found. According to the EUCAST clinical breakpoints, all C. albicans isolates were susceptible to almost all commonly used antifungal drugs, with attention to the major host and pharmacodynamic facts an ideal condition for a favorable clinical outcome.  Despite these inoffensive results, a close examination of the usefulness and advantages of antifungal susceptibility testing showed the necessity of routine testing and scanning for emerging resistances as a main pillar of antifungal stewardship. Next to the limited and considerate use of antifungal drugs, susceptibility testing can help to prevent a problematic increase of resistances, especially considering non-albicans Candida species.             
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6 Conclusions In the years between 2005 and 2012, 99 Candida spp. isolates were gathered from the bloodstream of patients in the university hospital Würzburg. Initially, all isolates were presumed to be C. albicans specimens. Retrospective species identification revealed that three isolates contained C. dubliniensis and two specimens were mixed cultures of C. glabrata and C. albicans. Possible sources and consequences of misidentification and the importance of an accurate and timely identification of Candida bloodstream infections on species level were discussed previously in the thesis, but are not the major aim of this project. All 95 C. albicans isolates were molecularly analyzed with the MLST method. Typing results were subsequently added to the MLST online database. The majority of the isolates (79%) featured an allelic profile that was not previously described and consequently added as a new DST to the database. Seven DSTs were assigned to more than one isolate, thereupon the patient data from these isolates were reviewed concerning the possibility of nosocomial transmission. This investigation produced no sign of a patient-to-patient strain transmission, a result that was expected due to the fact that proven cases of nosocomial transmission of C. albicans were not published yet. Our results showed unambiguously that MLST is an appropriate tool to investigate nosocomial transmission and the progression of invasive infections. A phylogenetic analysis of the MLST data with the eBurst algorithm distributed the isolates widely in several clonal clusters, hinting that the strains are genetically heterogeneous and not closely related. In résumé, MLST is a well standardized and reliable method suitable for epidemiological and phylogenetic analysis and the detailed characterization of C. albicans isolates. Finally, all C. albicans isolates were tested for their susceptibility against common antifungal drugs. According to CLSI and EUCAST recommendations, Etests and a microdilution method were used to conduct the analysis. Except for some insignificant aberrations in case of itraconazole, no unusual tolerances against antifungal medication were found in the 95 isolates. Considering the sparse frequency of innate or acquired resistance in C. albicans, this result was not unexpected. Interestingly, we found no correlation between anidulafungin and caspofungin MICs, a fact that renders the commonly published recommendation to equalize anidulafungin or micafungin susceptibility with caspofungin susceptibility questionable. Although antifungal susceptibility test are, as previously discussed, not ideal for patient-specific candidemia treatment recommendations, they are an important epidemiological tool 
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for the development of general treatment recommendations and the surveillance of emerging resistances.                       
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